Fasenra results hint at new use in rare disorders

AstraZeneca’s (LSE: AZN) approved asthma therapy Fasenra (benralizumab) looks likely to provide a much-needed treatment for a group of rare, potentially fatal disorders.

Classed under the name, hypereosinophilic syndrome (HES), the disorders are characterized by high numbers of eosinophils in blood and tissues which can cause progressive, potentially life-threatening organ damage.

"The data are potentially important given the limited treatment options for this debilitating disease"The goal of HES treatment is to deplete eosinophils in the blood and tissues, prevent organ damage and slow disease progression.